Use of dasatinib dose-reduction periods to remedy poor surgical wound healing in Philadelphia chromosome-positive acute lymphoblastic leukemia

Kandice E. Roberts, Michael W. Deininger, Gerhard C. Hildebrandt, Brian K. Gackenbach, Maxwell M. Krem

Research output: Contribution to journalLetterpeer-review

Original languageEnglish
Pages (from-to)3507-3510
Number of pages4
JournalLeukemia and Lymphoma
Volume61
Issue number14
DOIs
StatePublished - 2020

Bibliographical note

Funding Information:
GCH reports research support from Takeda, Pharmacyclics, Jazz, Astellas, and Incyte and stock ownership of Bristol-Myers Squibb. MWD reports research support from NIH, R01CA178397.

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Fingerprint

Dive into the research topics of 'Use of dasatinib dose-reduction periods to remedy poor surgical wound healing in Philadelphia chromosome-positive acute lymphoblastic leukemia'. Together they form a unique fingerprint.

Cite this